索拉非尼联合化疗治疗原发性肝癌的临床研究  

Clinical study of sorafenib combined with chemotherapy for hepatocelIular carcinoma

作　　者：何丽平[1] 翟凤钰[1] 

机构地区：[1]濮阳市油田总医院,河南濮阳457001

出　　处：《中国医药科学》2013年第22期63-65,共3页China Medicine And Pharmacy

摘　　要：目的：探讨索拉非尼联合表阿霉素、氟尿嘧啶治疗原发性肝癌的临床疗效和安全性。方法回顾性分析我院自2003年2月～2010年2月收治的56例原发性肝癌患者，随机分为治疗组及对照组各28例。治疗组：索拉菲尼联合EF方案；对照组单用索拉菲尼，比较两组的总体疗效及不良反应发生率。结果治疗组在有效率、疾病控制率、中位无进展生存时间、中位生存期、1年生存率均优于对照组，差异有统计学意义（P＜0.05）；两组的主要不良反应均为疲乏、高血压、手足皮肤反应、腹泻等，治疗组较对照组除了白细胞减少及恶心、呕吐略差外（P＜0.05），两组间其他不良反应差异无统计学意义（P＞0.05）。结论索拉非尼联合（EF方案）化疗治疗原发性肝癌的近期疗效高，安全性好，患者耐受性好，值得临床进一步研究。Objective To observe the clinical efficacy and safety of sorafenib combined with chemotherapy for hepatocellular carcinoma. Methods 56 patients with Hepatocelular Carcinoma admitted in our hospital from February 2003 to February 20l0,were randomly divided into the treatment group and the control.The treatment group was interfered with sorafenib combined with EF;The control group was treated with sorafenib. Overall efficacy and incidence of adverse reactions were compared. Results The treatment group is more efficacy than the control group in The effective rate （CR＋PR）,control rate,median follow-up time,median progression-free survival （PFS）,median survival （OS）and 1 year survival rate is better in treatment than those in the control,The difference was statistically significant （P〈0.05）.The major adverse reactions in both groups were fatigue,hypertension,hand-foot skin reaction,diarrhea,etc.In addition,leukopenia,nausea and vomiting were more popular than those in the control（P〈0.05）,other adverse reactions in both groups were not statistically significant（P 〉 0.05）. Conclusion Sorafenib combined with （EF program） chemotherapy was more efficacy,safety,and well tolerated in the treatment of HepatocelIular Carcinoma.

关 键 词：索拉非尼 化疗治疗 原发性肝癌 

分 类 号：R735.7[医药卫生—肿瘤]